Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.
Sylvie Bonvalot, MD, PhD, HDR
Advertisement
Articles by Sylvie Bonvalot, MD, PhD, HDR
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
4
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
5